†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

BUSINESS DESCRIPTIONNYCOMED MARKETSNORDIC / CISBranded Rx includes the marketing & sale of prescription only pharmaceuticals,mainly to prescribing MDs and hospitals. Only products receiving product specificpromotion and / or support are included in the business area. The growth inrevenues in 2000 was 16%.Branded Pharmacy includes the marketing & sale of OTC and non-registered productssold through pharmacies only. The products are promoted towards thefinal consumer as well as supported through point-of-sale activities and pharmacychain key account activities. The growth in revenues in 2000 was 7%.Consumer Health includes the marketing & sale of health care related productsthrough other channels than the pharmacy. The products are primarily promotedto the consumer, with the trade being an important stakeholder. The growth inrevenues in 2000 was 18%.Portfolio includes the unbranded, often generic portfolio of products not receivingproduct specific promotion support. Maintenance marketing activities will occur,mainly of a relationship nature, as well as tender competition activities. The productportfolio in this business will continuously be evaluated for product pruningand de-listing. The Portfolio Business area had a decrease in revenues in 2000of 1%.Finland & the Baltic states are currently organised on a country basis as a consequenceof small domestic organisations. Both Finland and the Baltic countrieshave been showing very rapid growth in revenues. The growth in 2000 was 68%for Finland and 31% for the Baltic countries. With the Joint Venture agreementwith Leiras Oy, we have suddenly grown substantially in size in Finland. If progressis according to plan, Finland is likely to be included in the pan NordicMarketing and Sales organisation in 2003.–17–